Veriheal

MARCH 20, 2023

While decriminalization decreases the negative impact of legal issues, it does not provide accessible, safe, and regulated psilocybin for those seeking treatment. Andy Smith (D) stated that he is “working on a bill forming a psychedelic medicine task force so Minnesotans can access these life-affirming treatments. Missouri Rep.

Clinical Trials 98

Clinical Trials Therapy Decriminalization Treatment 98

Veriheal

MARCH 2, 2024

In December of 2023, the country recently made a new move towards reform that could stimulate the cannabidiol (CBD) industry and provide many patients, such as those with epilepsy , with access to potentially life-changing medical treatments. and Europe to treat severe epilepsy, as well as other medical conditions.

Legalization 105

Legalization Epilepsy Clinical Trials THC 105

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Stay tuned… Oregon plans to accept applications for Facilitators, Laboratories, Manufacturers and Service Centers starting January 2023. Schedule I.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

SEPTEMBER 22, 2021

Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

OCTOBER 4, 2021

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

MAY 12, 2022

Lophora has previously secured grant funding from the BioInovation Institute (Novo Nordisk Foundation) and continues to characterise its lead candidates, aiming to initiate clinical trials in 2023. Lophora expects LPH-5 to be IND ready in Q4 2022 and plans to begin first-in-human trials in 2023.

Medicine 52

Medicine Research and Development Clinical Trials Treatment 52